Your Vision Is Blurry, but Your Eyes Look Fine. Here's the Biological Reason.

Your retina is immune-privileged territory. It needs to be protected from the body’s own inflammatory defenses, which are powerful enough to destroy the delicate cells that detect light. Complement Factor H (CFH) is one of your retina’s primary peacekeepers. It suppresses excessive complement activation, preventing immune cells from attacking your own photoreceptor cells and the supporting tissue beneath them.

The Y402H variant in CFH, carried by roughly 30-40% of people in European ancestry populations, significantly impairs this immune regulation. People with the H allele have a substantially higher risk of age-related macular degeneration because their retinas mount an excessive inflammatory response to normal metabolic byproducts. This chronic low-level inflammation accelerates the death of photoreceptor cells and the retinal pigment epithelium that supports them.

You experience this as floaters that increase over months and years, often accompanied by a subtle haziness in your central vision. You might notice that bright light irritates your eyes more than it used to, or that you’re slightly more sensitive to glare. These are signs that your retinal immune system is overactive and your photoreceptors are under inflammatory stress.

Your retina is the most metabolically demanding tissue in your body. It needs constant oxygen and glucose delivery to power the billions of light-detection events happening every second. VEGF (Vascular Endothelial Growth Factor) is your retina’s master signal for building and maintaining the capillary network that delivers this oxygen. Without adequate VEGF signaling, your retinal blood vessels don’t form properly, and the photoreceptors they feed become hypoxic.

The -634G>C variant in VEGF, present in roughly 35% of the population, reduces VEGF expression and impairs retinal neovascularization. This means your retina has a compromised ability to build new blood vessels in response to metabolic demand or to repair damaged capillaries. The result is chronic hypoxia in your photoreceptor layer, which triggers both oxidative stress and the release of more VEGF, setting off a cycle of vascular instability.

You notice this as floaters that seem to increase in certain lighting conditions, particularly when you’re tired or dehydrated. You might also notice that your eyes feel strained more easily, that reading requires more effort, or that your vision seems to fluctuate slightly throughout the day depending on how well-oxygenated your retina is.

Your retina accumulates lipid-rich debris as photoreceptors are recycled and renewed. Apolipoprotein E (APOE) is the cleanup crew, responsible for transporting oxidized lipids out of the retina and preventing them from accumulating as drusen, the telltale deposits of macular degeneration. APOE also regulates neuroinflammation and protects photoreceptors from death when they’re under stress.

The APOE4 allele, present in roughly 25-30% of European ancestry populations, is significantly less efficient at these protective functions. People carrying the E4 variant have impaired lipid clearance from their retinas and reduced neuroprotection against oxidative stress. This combination accelerates the progression from occasional floaters to visible drusen and measurable vision loss.

You experience this as floaters that seem to cluster in one area, often slightly below the center of your vision where the macula is most densely packed with photoreceptors. You might also notice that your night vision is declining, that your eyes take longer to adjust from bright light to dim conditions, and that you have increasing difficulty with reading small text even with correct glasses.

Vitamin D is not just a hormone for bone health. It’s a master immunoregulator in your retina, where it dampens excessive inflammation and maintains the delicate balance between immune tolerance and immune defense. The Vitamin D Receptor (VDR) is the lock that vitamin D binds to, and genetic variants in this receptor profoundly affect how well your retina can regulate its own immune environment.

The FokI VDR variant, present in roughly 40-50% of the population (the shorter allele is more common in some ancestry groups), produces a less efficient vitamin D receptor protein. People with the shorter allele have impaired vitamin D signaling in their retinal cells and a higher baseline of inflammatory cytokine production. This chronic low-level inflammation accelerates photoreceptor death and increases your susceptibility to both floaters and eventual vision loss.

You notice this as floaters that worsen seasonally, particularly in winter when sunlight exposure and vitamin D production are lowest. You might also notice that your eyes feel drier, that you’re more sensitive to fluorescent light, and that visual stress builds up more quickly when you’re working on screens.

Your retina has the highest blood flow per unit tissue of any organ in your body. That blood flow is controlled by nitric oxide (NO), a signaling molecule produced by your endothelial cells that tells blood vessels to relax and stay open. MTHFR (Methylenetetrahydrofolate Reductase) is upstream of this process. It converts folate into the form your cells use for methylation reactions, including the production of tetrahydrofolate (BH4), a critical cofactor for nitric oxide synthase. When MTHFR is impaired, nitric oxide production drops, and your retinal blood vessels constrict.

The C677T variant in MTHFR, carried by roughly 40% of people in European ancestry populations, reduces enzyme efficiency by 40-70%. This impairs both methylation capacity and nitric oxide synthesis, leading to chronic vasoconstriction in your retinal capillaries. The resulting hypoxia and reduced waste clearance accelerate oxidative stress in your photoreceptors.

You experience this as floaters that increase after physical or mental exertion, that worsen when you’re stressed or haven’t eaten enough protein, and that seem to correlate with fatigue or brain fog. You might also notice that your eyes tire quickly when reading or doing detailed work, that you have occasional blurred vision that resolves after rest, and that you feel more visually sensitive when your energy levels are low.

Your photoreceptor cells are mitochondrial powerhouses. They have more mitochondria per unit volume than almost any other cell type because they need constant ATP to power the light-detection machinery in their outer segments. But this high energy demand comes with a cost: massive production of reactive oxygen species (ROS), the free radicals that damage cellular machinery. SOD2 (Superoxide Dismutase 2) is your photoreceptors’ primary mitochondrial antioxidant, converting the most dangerous free radical (superoxide) into hydrogen peroxide, which is then handled by catalase and glutathione peroxidase.

The Val16Ala variant in SOD2, present in roughly 40% of the population as the homozygous variant, produces a less efficient mitochondrial antioxidant enzyme. People with the Ala16Ala genotype have significantly reduced mitochondrial antioxidant capacity in their retinal cells, leaving their photoreceptors chronically under oxidative stress. This accelerates both the breakdown of photoreceptors and the accumulation of lipofuscin, the toxic brown pigment that marks cellular aging.

You experience this as floaters that increase steadily and predictably, worsening with any factor that increases metabolic stress: intense screen time, prolonged bright light exposure, poor sleep, or high-intensity exercise without adequate recovery. You might also notice that you have a harder time recovering from eye strain, that your vision seems slightly hazier at the end of the day, and that your floaters seem to correlate with your overall energy levels.